At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 192 enrolled
Drug / intervention
ASTX029 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating ASTX029 for Solid Tumor, Adult. Completed, enrolled 192 participants across 31 sites in 4 countries.
Detailed Summary
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to participants with advanced solid malignancies who are not candidates for approved or available therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult
CountriesFrance, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedMay 2018
Primary CompletionAug 2024
Study CompletionMar 2025
TodayJul 2026
First PostedMay 9, 2018
Enrollment StartMay 7, 2018
Primary CompletionAug 1, 2024
Study CompletionMar 3, 2025
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 8.1 years ago
Interventions
ASTX029drug
PiB
ASTX029drug
Tablet